Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADMS
  • CUSIP: N/A
  • Web:
  • Market Cap: $347.01 million
  • Outstanding Shares: 22,359,000
Average Prices:
  • 50 Day Moving Avg: $16.27
  • 200 Day Moving Avg: $16.50
  • 52 Week Range: $12.10 - $19.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.05
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $397,000.00
  • Price / Sales: 874.08
  • Book Value: $5.36 per share
  • Price / Book: 2.90
  • EBIDTA: ($64,670,000.00)
  • Net Margins: -5,267.99%
  • Return on Equity: -38.31%
  • Return on Assets: -35.25%
  • Current Ratio: 8.79%
  • Quick Ratio: 8.79%
  • Average Volume: 135,695 shs.
  • Beta: 0.72
  • Short Ratio: 29.44

Frequently Asked Questions for Adamas Pharmaceuticals (NASDAQ:ADMS)

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.72) earnings per share for the quarter, meeting the consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative return on equity of 38.31% and a negative net margin of 5,267.99%. During the same period in the previous year, the business earned ($0.65) earnings per share. View Adamas Pharmaceuticals' Earnings History.

Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 1-year price objectives for Adamas Pharmaceuticals' shares. Their predictions range from $21.00 to $44.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $30.80 in the next year. View Analyst Ratings for Adamas Pharmaceuticals.

What are analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (5/12/2017)
  • 2. Mizuho analysts commented, "We expect the stock to appreciate into the August 24 PDUFA of ADS-5102 since we think there is limited risk in front of this event for the company, and also because of the scarcity value of pre-launch neurology assets. As we see it, there are two key remaining risks that could derail FDA approval: 1) manufacturing risk, since Adamas has not yet validated its commercial manufacturing process (mgmt. indicated inspections are ongoing and it has nothing negative to disclose); and 2) emergence of a concerning safety finding that appears novel to the FDA relative to what is already known about generic amantadine (mgmt. indicated there have been no drug-related deaths in the trial and all adverse events are consistent with what is known about amantadine, including suicidality). Mgmt. does not expect an Advisory Panel. We reiterate our Buy rating and $26 PT." (3/15/2017)

Who are some of Adamas Pharmaceuticals' key competitors?

Who owns Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (0.00%), Vanguard Group Inc. (0.00%), Alliancebernstein L.P. (0.00%), Emerald Mutual Fund Advisers Trust (2.57%), Emerald Advisers Inc. PA (2.33%) and Granite Point Capital Management L.P. (0.00%). Company insiders that own Adamas Pharmaceuticals stock include Gregory T Went, Ivan M Lieberburg, Ix Lp Mdv, Natalie Mcclure, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Who sold Adamas Pharmaceuticals stock? Who is selling Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sphera Funds Management LTD., Alliancebernstein L.P., Cheyne Capital Management UK LLP, JPMorgan Chase & Co., Morgan Stanley and Granite Point Capital Management L.P.. Company insiders that have sold Adamas Pharmaceuticals stock in the last year include Gregory T Went, Rajiv Patni and William J Dawson. View Insider Buying and Selling for Adamas Pharmaceuticals.

Who bought Adamas Pharmaceuticals stock? Who is buying Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Parametric Portfolio Associates LLC, Vanguard Group Inc., Goldman Sachs Group Inc., Trexquant Investment LP, Geode Capital Management LLC, Wells Fargo & Company MN and Bank of New York Mellon Corp. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy Adamas Pharmaceuticals stock?

Shares of Adamas Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Adamas Pharmaceuticals stock cost?

One share of Adamas Pharmaceuticals stock can currently be purchased for approximately $15.52.

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.17)
Consensus Price Target: $30.80 (98.45% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Noble FinancialReiterated RatingBuyLowView Rating Details
3/15/2017MizuhoReiterated RatingTop Pick$26.00LowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
7/25/2016Credit Suisse Group AGReiterated RatingBuy$21.00N/AView Rating Details
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00N/AView Rating Details
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/AView Rating Details
5/12/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
9/11/2015William BlairReiterated RatingOutperform$35.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Earnings History by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.72)($0.72)$0.11 millionViewListenView Earnings Details
2/28/2017Q4($0.80)($0.68)$0.17 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.71)($0.78)$0.18 million$0.22 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)$0.18 millionViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)$0.10 million$0.52 millionViewN/AView Earnings Details
11/12/2015Q3($0.79)($0.81)$0.10 million$0.77 millionViewN/AView Earnings Details
8/11/2015Q215($0.67)($0.78)$0.10 million$0.40 millionViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)$0.10 million$0.23 millionViewN/AView Earnings Details
3/3/2015Q4 2014$0.64$0.50$30.18 million$30.30 millionViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)$0.18 million$0.22 millionViewN/AView Earnings Details
8/7/2014Q214$2.07$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
2017 EPS Consensus Estimate: ($3.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.64)($0.64)($0.64)
Q2 20171($0.84)($0.84)($0.84)
Q3 20171($0.96)($0.96)($0.96)
Q4 20171($1.04)($1.04)($1.04)
(Data provided by Zacks Investment Research)


Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Ownership Percentage: 31.79%
Institutional Ownership Percentage: 75.44%
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Gregory T WentCEOSell2,807$17.03$47,803.21View SEC Filing  
3/21/2017Rajiv PatniInsiderSell733$17.04$12,490.32View SEC Filing  
3/21/2017William J DawsonCFOSell716$17.02$12,186.32View SEC Filing  
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Adamas Pharmaceuticals (NASDAQ:ADMS)
Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline logoAdamas Epilepsy Drug Shows Positive Result in Phase Ia Study - May 23 at 3:22 PM logoAdamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy - May 22 at 3:21 PM logoAdamas Pharmaceuticals Inc (ADMS) Stock Rating Reaffirmed by Noble Financial - May 13 at 11:32 AM logoAdamas Pharmaceuticals Inc (ADMS) Lowered to "Sell" at Zacks Investment Research - May 12 at 8:56 PM logoAdamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from Analysts - May 12 at 6:42 PM logoAdamas Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.84) Per Share, William Blair Forecasts (ADMS) - May 12 at 10:42 AM logoAdamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2017 Results - Earnings Call Transcript - May 11 at 3:35 PM logoAdamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners - May 11 at 3:35 PM logoAdamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners - May 11 at 3:35 PM logoEdited Transcript of ADMS earnings conference call or presentation 9-May-17 8:30pm GMT - May 11 at 3:35 PM logo[$$] Adamas Receives $100 Million Royalty-Backed Financing From HealthCare Royalty Partners - May 11 at 3:35 PM logoAdamas Pharmaceuticals Inc (ADMS) Releases Earnings Results, Hits Expectations - May 10 at 9:14 PM logoAdamas Pharmaceuticals Inc (ADMS) Expected to Post Quarterly Sales of $580,000.00 - May 10 at 11:34 AM logoAdamas Reports Recent Achievements and First Quarter 2017 Financial Results - May 9 at 8:21 PM logoAdamas reports 1Q loss - May 9 at 6:45 PM logoInvestor Network: Adamas Pharmaceuticals, Inc. to Host Earnings Call - May 9 at 3:20 PM logo Analysts Expect Adamas Pharmaceuticals Inc (ADMS) to Announce -$0.72 EPS - May 8 at 10:50 AM logoAdamas Pharmaceuticals Inc (ADMS) Scheduled to Post Earnings on Tuesday - May 7 at 7:02 AM logoAdamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : May 5, 2017 - May 5 at 8:21 PM logoAdamas Reports Inducement Grant to New Chief Operating Officer - May 5 at 8:21 PM logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : May 4, 2017 - May 4 at 3:21 PM logoAdamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017 - May 3 at 6:59 AM logoAdamas Pharmaceuticals (ADMS) Getting Positive News Coverage, Study Finds - May 2 at 9:18 AM logoAdamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 - April 27 at 8:39 PM logoAdamas Pharmaceuticals (ADMS) Given Daily Media Sentiment Score of 0.26 - April 27 at 9:34 AM logoAdamas Pharmaceuticals (ADMS) Earns Daily Media Sentiment Rating of 0.31 - April 24 at 11:48 AM logoAdamas Pharma (ADMS) Reports Positive ADS-5102 Pooled Phase 3 Data - April 24 at 11:11 AM logoAdamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease - April 24 at 11:11 AM logoAdamas Pharmaceuticals (ADMS) Given News Sentiment Rating of 0.01 - April 21 at 8:19 AM logo Brokerages Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Post Quarterly Sales of $570,000.00 - April 19 at 11:56 AM logoAdamas Pharmaceuticals Inc (ADMS) Given Consensus Recommendation of "Buy" by Brokerages - April 17 at 6:37 PM logoZacks: Brokerages Expect Adamas Pharmaceuticals Inc (ADMS) Will Announce Earnings of -$0.72 Per Share - April 17 at 11:56 AM logoAdamas Pharmaceuticals (ADMS) Earning Somewhat Favorable Press Coverage, Study Shows - April 13 at 11:37 AM logoAdamas Pharmaceuticals (ADMS) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 6:31 AM logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : April 5, 2017 - April 7 at 6:31 AM logoAdamas Pharmaceuticals Inc (ADMS) Short Interest Update - April 6 at 11:51 AM logoAdamas Pharmaceuticals Inc (ADMS) Short Interest Update - April 6 at 11:51 AM logoAdamas Pharmaceuticals: Runup To Approval - Seeking Alpha - April 3 at 3:31 PM logoAdamas Pharma (ADMS) to Present ADS-5102 Data at Academy of Managed Care Pharmacy 2017 Annual Meeting on 3/27 - March 28 at 8:22 PM logoAdamas Pharma (ADMS) to Present ADS-5102 Data at Academy of Managed Care Pharmacy 2017 Annual Meeting on ... - - March 28 at 3:20 PM logoAdamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting - March 28 at 3:20 PM logoAdamas Pharmaceuticals Inc (ADMS) Insider Sells $12,490.32 in Stock - March 22 at 8:31 PM logoAdamas Pharmaceuticals Inc (ADMS) CFO Sells $12,186.32 in Stock - March 22 at 8:31 PM logoAdamas Pharmaceuticals Inc (ADMS) CEO Sells $47,803.21 in Stock - March 22 at 8:06 PM logoAdamas Pharmaceuticals Inc (ADMS) Receives Average Rating of "Buy" from Analysts - March 22 at 11:32 AM logoAdamas Pharmaceuticals Inc (ADMS) Given "Top Pick" Rating at Mizuho - March 21 at 7:43 AM logoAre These 2 Biotechs Diamonds in the Rough? - March 16 at 4:52 PM logoAdamas Pharmaceuticals (ADMS) Remains Top Pick at Mizuho Into August 24 PDUFA - - March 15 at 3:25 PM logoMizuho Reaffirms Top Pick Rating for Adamas Pharmaceuticals Inc (ADMS) - March 15 at 2:57 PM logoADAMAS PHARMACEUTICALS INC Financials - March 4 at 3:20 PM



Adamas Pharmaceuticals (ADMS) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff